Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

focal segmental glomerulosclerosis (FGS) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

focal segmental glomerulosclerosis

MONDO:0100313

Also known as:FGSFGS (focal glomerular sclerosis)FSGS

Find Clinical TrialsTrials

Overview

A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.

TreatmentsNo approved treatments · 3 in pipeline

Clinical Trials33 registered · 25 recruiting

Patient Orgs1 organizations · NephCure

Diagnosis

Biomarker and diagnostic research for focal segmental glomerulosclerosis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for focal segmental glomerulosclerosis. An additional 3 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for focal segmental glomerulosclerosis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for focal segmental glomerulosclerosis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

33 clinical trials registered, 25 recruiting. Interventions under study include drug therapy, other interventions, and medical devices. Pipeline includes 1 PHASE4, 4 PHASE3, 9 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05505500](https://clinicaltrials.gov/study/NCT05505500)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:58 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Patient Advocacy Groups

View all PAGs →

NephCurePrimary Focus

USWebsite ↗

Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.

Are you a patient organization not listed here? Claim this page to be listed and embed this content on your site — free.

Medical References

External Resources

GARD

Genetic and Rare Diseases Info Center

GARD:6517

Questions for Your Care Team

→Are any of the 33 active clinical trials a good fit for my situation?
→With 3 compounds in the orphan drug pipeline, which are furthest along in development and which clinical trials should I be aware of?
→Are there specialists or centers of excellence for this condition in my area?
→How can I connect with NephCure and other patient organizations for support?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	91	25%
Laboratory research	89	24%
Patient case studies	47	13%
Clinical study results	41	11%
Disease patterns and progression	40	11%
Testing and diagnosis research	29	8%
New treatment approaches	15	4%
Other research	13	4%

Kisho

focal segmental glomerulosclerosis

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Rapidly progressive steroid-resistant focal segmental glomerulosclerosis associated with an INF2 exon 6 variant.

Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS.

Under-enrollment in rare kidney disease trials: lessons learned from the PRIVENT recurrent FSGS.

Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease

focal segmental glomerulosclerosis

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

External Resources

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Rapidly progressive steroid-resistant focal segmental glomerulosclerosis associated with an INF2 exon 6 variant.

Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS.

Under-enrollment in rare kidney disease trials: lessons learned from the PRIVENT recurrent FSGS.

Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease